PTLA Portola Pharmaceuticals Inc.

14.03
-0.34  -2%
Previous Close 14.37
Open 14.33
Price To Book 5.12
Market Cap 1,091,802,759
Shares 77,819,156
Volume 1,957,121
Short Ratio
Av. Daily Volume 1,534,573
Stock charts supplied by TradingView

NewsSee all news

  1. Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the

  2. Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 23, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.

  3. Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative

  4. Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  5. Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

    SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2a data presented at ASH December 9, 2019. ORR 48%; 76% in combo cohort.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the

  2. Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 23, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.

  3. Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative

  4. Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  5. Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

    SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  6. Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians

  7. Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  8. Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

  9. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 1, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as

  10. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  11. Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry

  12. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual